CA-NETAPP
16.3.2021 15:02:14 CET | Business Wire | Press release
Less than a year after joining global software leader NetApp (NASDAQ: NTAP) as its President, César Cernuda has announced changes to the go-to-market (GTM) model and global sales organization that will help steer the company into its cloud-led future.
Cernuda is instituting a customer- and partner-centric strategic and operational evolution that will allow NetApp to move to a customer engagement model focused on driving deeper specialization and delivering hybrid cloud expertise powered by digitization. The changes will see the company ramp up its efforts to drive consistency and simplicity across its global sales organization and more aggressively address key markets and segments while reaching new customers and partners.
“With today’s relentless pace of change, speed is the new scale. And that’s what organizations are demanding as they try to put their data to work to keep innovating and stay ahead of the digital curve,” said César Cernuda. “We are implementing these changes to better serve their needs. We will soon deliver a personalized, data-driven engagement model that allows our current and future customers to move at warp speed and aligns with the new way they want to engage with their solution partners.”
The evolution of NetApp’s sales organization will also result in changes and additions to the sales leadership team, effective May 1, 2021:
- NetApp veteran and former SVP, Globals, Verticals, and Pathways, Rick Scurfield will serve in the company’s newly established role of Chief Commercial Officer . Scurfield will be responsible for building a new GTM motion and strategy including direct sales and channel coverage and will drive the transformation of NetApp’s digital and virtual sales teams and Sales Operations to better enable NetApp’s sales force and worldwide partnerships. Scurfield has led winning sales organizations for more than 20 years, most recently growing and leading sales teams supporting NetApp’s largest global accounts, vertical segments, global pathways, and the U.S. Public Sector.
- Max Long , former SVP, Chief Customer Officer at Adobe, will be joining NetApp as the company’s new SVP, North America . Leveraging his 30+ years of experience building high-performance sales teams and leading business transformations. Long will continue the focus on aligning NetApp’s business objectives in the U.S. and Canada driven by our customer’s business requirements. He will lead direct sales, channel sales, and demand generation teams.
- Alex Wallner, also a NetApp veteran who most recently served as SVP, Worldwide Enterprise and Commercial Field Operations, will take on the newly created role of SVP, International . Wallner will lead the execution of all GTM activities for the EMEA, APAC and Latin America regions. Focusing on increasing the footprint of NetApp as the partner-of-choice for our international customers, he and his team will help customers address their data challenges with hybrid multi-cloud solutions including NetApp’s data center architectures and superior cloud software portfolio.
“Rick’s and Alex’s proven leadership and in-depth knowledge of our industry, our customers and our partners combined with Max’s track record of leading enterprise sales teams to success at scale will be instrumental in helping organizations everywhere unlock the best of today’s hybrid multi-cloud world, wherever they are on their digital transformation journey—on premises or in any cloud,” added Cernuda.
The evolution of the NetApp data-driven GTM model and cloud-led sales organization is expected to be a continuous process starting in Q1 FY22.
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005711/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom